Production (Stage)
VYNE Therapeutics Inc.
VYNE
$1.04
$0.044.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 106.12% | 10.53% | 6.14% | 46.67% | -1.01% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 106.12% | 10.53% | 6.14% | 46.67% | -1.01% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 106.12% | 10.53% | 6.14% | 46.67% | -1.01% |
| SG&A Expenses | -13.13% | -18.40% | -2.18% | 2.11% | 16.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.69% | 86.07% | 108.13% | 1.35% | 25.18% |
| Operating Income | -24.62% | -86.91% | -109.99% | -0.76% | -25.62% |
| Income Before Tax | -37.85% | -95.22% | -100.25% | 6.41% | -11.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -37.85% | -95.29% | -100.25% | 6.41% | -11.21% |
| Earnings from Discontinued Operations | 0.00% | 77.78% | -- | 45.00% | 20.00% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.80% | -94.28% | -84.64% | 6.48% | -11.15% |
| EBIT | -24.62% | -86.91% | -109.99% | -0.76% | -25.62% |
| EBITDA | -- | -87.39% | -- | -- | -- |
| EPS Basic | -37.47% | -39.29% | 85.77% | 92.81% | 91.50% |
| Normalized Basic EPS | -37.55% | -43.37% | 84.57% | 92.80% | 91.50% |
| EPS Diluted | -37.47% | -39.29% | 85.77% | 92.81% | 91.50% |
| Normalized Diluted EPS | -37.55% | -43.37% | 84.57% | 92.80% | 91.50% |
| Average Basic Shares Outstanding | 0.22% | 36.18% | 1,197.59% | 1,200.73% | 1,208.17% |
| Average Diluted Shares Outstanding | 0.22% | 36.18% | 1,197.59% | 1,200.73% | 1,208.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |